Drug Trial Radar · NCT01717326
A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)
Last checked: Nov 19, 2026Latest source record: Feb 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
573
Actual
Start
Feb 7, 2013
Primary completion
Feb 23, 2015
Study completion May 6, 2015
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 30, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study of the safety and efficacy of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) ± ribavirin (RBV). The primary efficacy endpoint will be Sustained Virologic Response 12 weeks after the end of all study therapy (SVR12) in each of the treatment arms.
Conditions
- Hepatitis C
Interventions
GrazoprevirDrug
100 mg tablet orally QD
ElbasvirDrug
Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD
Placebo to ElbasvirDrug
Placebo to Elbasvir 20 or 50 mg capsule, orally, once daily for 12 weeks to maintain blind (Part A only)
RibavirinDrug
Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After the End of All Study Therapy (SVR12)Time frame: 12 weeks after end of therapy (up to 30 weeks)
- Percentage of Participants Experiencing at Least One Adverse Event (AE) During the Treatment Period and First 14 Follow-up DaysTime frame: From Day 1 [post-dose] through 14 days following last dose of study drug (up to 20 weeks)
- Percentage of Participants Discontinuing Study Therapy Due to an AE During the Treatment Period and First 14 Follow-up DaysTime frame: From Day 1 [post-dose] through 14 days following last dose of study drug (up to 20 weeks)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.